The Trump administration is ending a Medicare drug subsidy program. Here's how it could affect costs

The Trump administration is ending a Medicare drug subsidy program that lowered prescription drug costs for 25 million seniors, leading to potential higher monthly premiums in 2027. The program, initially implemented by the Biden administration in 2024, was a response to the 2022 Inflation Reduction Act. Democrats criticized the decision as increasing costs for seniors, while CMS claims the impact will be minimal, with most beneficiaries seeing less than a $10 monthly increase.